U.S. regulators have cleared Moderna Therapeutics’ mRNA-1273 potential Covid-19 vaccine candidate for second-stage study.

  • The Food and Drug Administration said it’s completed its phase-one safety review for Moderna’s mRNA-1273 vaccine candidate and has authorized the start of a second stage study.
  • Moderna CEO Stephane Bancel said, “Moderna is now preparing to potentially have its first [vaccine] approved as soon as 2021.”
  • Moderna was given $483 million in federal funding last month to develop a coronavirus vaccine.